This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Investigating the recent post-approval data on LUMRYZ and Xywav in patients with narcolepsy presented at World Sleep 2023.

Ticker(s): AVDL, JAZZ

Who's the expert?

  • Treat ailments of the lungs and respiratory system, such as asthma, pneumonia, tuberculosis, complicated chest infections and chronic obstructive pulmonary diseases including emphysema.
  • D.O. Pulmonologist in Rochester, NY and has over 18 years of experience in the medical field.
  • Has extensive experience in Obstructive Lung Disease and Sleep Apnea.

Interview Goal
to discuss the current standard of care and the use of LUMRYZ (sodium oxybate) and Xywav (calcium, magnesium, potassium, and sodium oxybates) as treatments for narcolepsy including the recent post-approval data on LUMRYZ and Xywav presented at World Sleep 2023.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.